Comparative analysis of Etest and broth microdilution method (AFST-EUCAST) for trends in antifungal drug susceptibility testing of Brazilian Cryptococcus neoformans isolates

Journal of Medical Microbiology

Volumn 55, Issue 12, 2006, Pages 1693-1699

  Dias, Amanda L T ^a,b   Matsumoto, Flavia E ^a   Melhem, Marcia S C ^c   Da Silva, Eriques G ^a   Auler, Marcos E ^a   De Siqueira, Antonio M ^b   Paula, Claudete R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF ALFENAS   (Brazil)

^c INSTITUTO ADOLFO LUTZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BRAZIL; BROTH MICRODILUTION; COMPARATIVE STUDY; CRYPTOCOCCUS NEOFORMANS; DILUTION; DOSE RESPONSE; E TEST; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY CONTROL; STATISTICAL ANALYSIS;

ANTIFUNGAL AGENTS; BRAZIL; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; HUMANS; MICROBIAL SENSITIVITY TESTS; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY;

EID: 33845449491     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.46789-0     Document Type: Article

References (41)

1. Abdel Salam, H. A. (2005). In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs. Mycoses 48, 327-32.
2. Aller, A. I., Martin-Mazuelos, E., Lozano, F., Gomez-Mateos, J., Steele-Moore, L., Holloway, W. J., Gutiérrez, M. J., Recio, F. J. & Espinel-Ingroff, A. (2000). Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother 44, 1544-1548.
3. Andes, D. (2003). In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother 47, 1179-1186.
4. Andes, D., Marcillo, K., Stamstad, T. & Conklin, R. (2003). In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 47, 3165-3169.
5. Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing (2002). Method for Determination of Minimal Inhibitory Concentration (MIC) by Broth Dilution of Fermentative Yeast, discussion document E.Dis7.1. Taufkirchen: European Society of Clinical Microbiology and Infectious Diseases.
6. Berg, J., Clancy, C. J. & Nguyen, M. H. (1998). The hidden danger of primary fluconazole prophylaxis for patients with AIDS. Clin Infect Dis 26, 186-187.
7. Brandt, M. E., Pfaller, M. A., Hajjeh, R. A., Hamill, R. J., Pappas, P. G., Reingold, A. L., Rimland, D. & Warnock, D. W. for the Cryptococcal Disease Active Surveillance Group (2001). Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob Agents Chemother 45, 3065-3069.
8. Brass, C., Shainhouse, J. Z. & Stevens, D. A. (1979). Variability of agar dilution-replicator method of yeast susceptibility testing. Antimicrob Agents Chemother 15, 763-768.
9. Casadevall, A. & Perfect, J. R. (1998). Cryptococcus neoformans, 1st edn. Washington, DC: American Society for Microbiology.
10. Chryssanthou, E., Gronfors, C. & Khanna, N. (1997). Comparison of broth macrodilution, broth microdilution and E-test susceptibility tests of Cryptococcus neoformans for fluconazole. Mycoses 40, 423-427.
11. Clinical and Laboratory Standards Institute (2002). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Approved Standard, 2nd edn, M27-A2. Wayne, PA: Clinical and Laboratory Standards Institute.
12. Clinical and Laboratory Standards Institute (2005). Quality Control Minimal Inhibitory Concentration (MIC) Limits for Broth Microdilution and MIC Interpreative Breakpoints, M27-S2. Wayne, PA: Clinical and Laboratory Standards Institute.
13. Colombo, A. L., Barchiesi, F., McGough, D. A. & Rinaldi, M. G. (1995). Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. J Clin Microbiol 33, 535-540.
14. Cuenca-Estrella, M., Moore, C. B., Barchiesi, F. & 12 other authors (2003). Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect 9, 467-474.
15. Espinel-Ingroff, A. (1998). In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 36, 198-202.
16. Espinell-Ingroff, A., Pfaller, M., Erwin, M. E. & Jones, R. N. (1996). Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeast to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose. J Clin Microbiol 34, 848-852.
17. Espinel-Ingroff, A., Barchiesi, F., Cuenca-Estrella, M., Pfaller, M. A., Rinaldi, M., Rodriguez-Tudela, J. L. & Verweij, P. E. (2005). International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J Clin Microbiol 43, 3884-3889.
18. Ghannoun, M. A., Ibrahim, A. S., Fu, Y., Shafiq, M. C., Edwards, J. E. & Criddle, R. S. (1992). Susceptibility testing of Cryptococcus neoformans: a microdilution technique. J Clin Microbiol 30, 2881-2886.
19. Groll, A. H. & Kolve, H. (2004). Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. Eur J Clin Microbiol Inject Dis 23, 256-270.
20. Hitchcock, C. A., Andrews, R. J., Lewis, B. G. H. & Troke, P. F. (1995). UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity in experimental infections with Cryptococcus. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, abstract F75, p. 126. Washington, DC: American Society for Microbiology.
21. Hoban, D. J., Zhanel, G. G. & Karlowsky, J. A. (1999). In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients. Antimicrob Agents Chemother 43, 1463-1464.
22. Johnson, L. B. & Kauffman, C. A. (2003). Voriconazole: a new triazole antifungal agent. Clin Infect Dis 36, 630-637.
23. Lozano-Chiu, M., Paetznick, V. L., Ghannoum, M. A. & Rex, J. H. (1998). Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performance of three different media assessed by using E-Test and National Committee for Clinical Laboratory Standards M27-A methodologies. J Clin Microbiol 36, 2817-2822.
24. McGinnis, M. R., Pasarell, L., Sutton, D. A., Fothergill, A. W., Cooper, R., Jr & Rinaldi, M. G. (1997). In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother 41, 1832-1834.
25. Nguyen, M. H. & Yu, C. Y. (1998). In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and resistant Cryptococcus neoformans isolates. Antimicrob Agents Chemother 42, 471-472.
26. Odds, F. C. (1980). Laboratory evaluation of antifungal agents: a comparative study of five imidazole derivatives of clinical importance. J Antimicrob Chemother 6, 749-761.
27. Perfect, J. R., Marr, K. A., Walsh, T. J. & 8 other authors (2003). Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36, 1122-1131.
28. Perkins, A., Gomes-Lopez, A., Mellado, E., Rodrigues-Tudela, J. L. & Cuenca-Estrella, M. (2005). Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. J Antimicrob Chemother 56, 1144-1147.
29. Petraitiene, R., Petraitis, V., Groll, A. H. & 7 other authors (2001). Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 45, 857-869.
30. Pfaller, M. A., Zhang, J., Messer, S. A., Brandt, M. E., Hajjeh, R. A., Jessup, C. J., Tumberland, M., Mbidde, E. K. & Ghannoum, M. A. (1999). In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother 43, 169-171.
31. Pfaller, M. A., Messer, S. A., Houston, A., Mills, K., Bolmström, A. & Jones, R. N. (2000). Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media. J Clin Microbiol 38, 3715-3717.
32. Pfaller, M. A., Walsh, T. J., Chaturvedi, V. & 7 other authors (2001). Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 14, 643-658.
33. Randhawa, H. S., Kowshik, T. & Khan, Z. U. (2003). Decayed wood of Syzygium cumini and Ficus religiosa living trees in Delhi/ New Delhi metropolitan area as natural habitat of Cryptococcus neoformans. Med Mycol 41, 199-209.
34. Revankar, S. G., Kirkpatrick, W. R., McAtee, R. K., Dib, O. P., Fothergill, A. W., Redding, S. W., Rinaldi, M. G. & Patterson, T. F. (1996). Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J Infect Dis 174, 821-827.
35. Rex, J. H., Pfaller, M. A., Walsh, T. J. & 8 other authors (2001). Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 14, 643-658.
36. Saag, M. S., Graybill, R. J., Larsen, R. A., Papaas, P. G., Perfect, J. R., Powderly, W. G., Sobel, J. D. & Dismukes, W. E. (2000). Practice guidelines for the management of cryptococcal diseases. Clin Infect Dis 30, 710-718.
37. Schwarz, P., Dromer, F., Lortholary, O. & Dannaoui, E. (2006). Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis. Antimicrob Agents Chemother 50, 113-120.
38. Vandenbossche, I., Vaneechoutte, M., Vandevenne, M., De Baere, T. & Verschraegen, G. (2002). Susceptibility testing of fluconazole by the NCCLS broth macrodilution method, E-test, and disk diffusion for application in the routine laboratory. J Clin Microbiol 40, 918-921.
39. Van Duin, D., Cleare, W., Zaragoza, O., Casadevall, A. & Nosanchuk, J. D. (2004). Effects of voriconazole on Cryptococcus neoformans. Antimicrob Agents Chemother 48, 2014-2020.
40. Warnock, D. W., Johnson, E. M. & Rogers, T. R. (1998). Multicentre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. J Antimicrob Chemother 42, 321-331.
41. Yildiran, S. T., Fothergill, A. W., Sutton, D. A. & Rinaldi, M. G. (2002). In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592). Mycoses 45, 378-383.